Principal Investigator: Peter Gottlieb MD, COMIRB # : 07-0927
The “Delay” Research Study is looking for people recently diagnosed with type 1 diabetes within the past 4-12 months.
This research study will use the medication hOKT3g1(Ala-Ala), also called Teplizumab, to see if we can change the immune system to maintain the body’s ability to produce some insulin.
Why should you consider this study?
- When you are first diagnosed with Type 1 Diabetes you still make some insulin
- Over time, your body will lose the ability to make this insulin
- This study will use a medication to try to keep your body making its own insulin
- This medication has been shown to extend the honeymoon period in new onset subjects
- While your body continues to make its own insulin, your diabetes will be easier to control
- Continued production of some insulin can decrease the risk for long term complications of type 1 diabetes
Who can sign up for this study?
- People recently diagnosed with Type 1 Diabetes within the past 4 – 12 months
- 8 years old – 30 years old
What will happen in this study?
- You will be assessed for general health and diabetes care
- If you qualify, you will receive treatment with study medication, or fake medication, once per day for 14 consecutive days
- You will be monitored for up to 2 additional years to look at your overall diabetes health
Who should I call with questions or to schedule an appointment?
Whitney Kastelic: 303-724-7502 or Whitney.Kastelic@ucdenver.edu
Lisa Meyers: 303-724-6732 or Lisa.Meyers@ucdenver.edu